MedTrace Logo

Pharmacokinetic Study of Doxorubicin in Children With Cancer

NCT01095926 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2013-06-28

No results posted yet for this study

Summary

Analyze pharmacokinetics of doxorubicin in children with cancer. Furthermore investigate the predictive role of troponin and natriuretic peptides for anthracycline-induced cardiotoxicity .

Conditions

Interventions

DRUG

doxorubicin

blood sampling before, during and after doxorubicin administration

Sponsors & Collaborators

  • University Hospital Muenster

    lead OTHER

Principal Investigators

  • Joachim Boos, MD, Prof. · University Hospital Muenster

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2013-02-28
Completion
2013-05-31

Countries

  • France
  • Germany
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01095926 on ClinicalTrials.gov